Pair Name	Parthenolide, Etoposide
Partner Name	Etoposide
Disease Info	[ICD-11: 2A60.Z]	Acute myeloid leukemia		Investigative
Biological Phenomena	Induction-->Oxidative Stress
Gene Regulation	Up-regulation	Expression	GSS	hsa2937
In Vitro Model	HL-60	Adult acute myeloid leukemia	Homo sapiens (Human)	CVCL_0002
Result	Parthenolide did not limit the cytotoxic effect of etoposide in HL-60 cells even in the case of antagonistic interaction. If parthenolide does increase GSH levels in combination with etoposide in the normal hematopoietic cells, it could protect them against the pro-oxidative effects of this anti-cancer drug.

Pair Name	Parthenolide, Balsalazide
Partner Name	Balsalazide
Disease Info	[ICD-11: 2B90]	Colon cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BCL-xL	hsa598
	Down-regulation	Expression	CASP3	hsa836
	Down-regulation	Expression	CASP8	hsa841
	Down-regulation	Expression	CASP9	hsa842
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	CFLAR	hsa8837
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Activity	NFKB1	hsa4790
	Down-regulation	Phosphorylation	NFKBIA	hsa4792
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Expression	PTGS2	hsa5743
	Up-regulation	Expression	TP53	hsa7157
	Down-regulation	Expression	VEGFA	hsa7422
In Vitro Model	HCT 116	Colon carcinoma	Homo sapiens (Human)	CVCL_0291
Result	These results demonstrate that parthenolide potentiates the efficacy of balsalazide through synergistic inhibition of NF-κB activation and the combination of dual agents prevents colon carcinogenesis from chronic inflammation.

Pair Name	Parthenolide, Doxorubicin
Partner Name	Doxorubicin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Inhibition-->Overexpression of both Nrf2 and its target activities
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	HSPA4	hsa3308
	Down-regulation	Expression	NFE2L2	hsa4780
	Down-regulation	Expression	SOD2	hsa6648
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
Result	PN prevented the acquisition of resistance induced by Mitox and DOX treatment in MDA-MB231 cells. This effect was mediated by inhibition of overexpression of both Nrf2 and its target activities. Therefore, within MDA-MB231 cell lines, PN not only exerts toxic effects on stem-like cells, which are responsible for tumour recurrence, but also prevents drug resistance

Pair Name	Parthenolide, Temozolomide
Partner Name	Temozolomide
Disease Info	[ICD-11: 2F7Z]	Glioma		Investigative
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	MGMT	hsa4255
	Down-regulation	Activity	NFKB1	hsa4790
	Up-regulation	Cleavage	PARP1	hsa142
In Vitro Model	T98G	Glioblastoma	Homo sapiens (Human)	CVCL_0556
	LN-18	Glioblastoma	Homo sapiens (Human)	CVCL_0392
Result	These findings suggest that NF-κB is a potential target for inducing cell death in gliomas. A targeted combination strategy in which the response to TMZ is synergistically enhanced by the addition of parthenolide which may be useful, especially in chemoresistant gliomas with high MGMT expression.

Pair Name	Parthenolide, Epirubicin
Partner Name	Epirubicin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Expression	CASP3	hsa836
In Vitro Model	MDA-MB-468	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0419
Result	According to lack of cytotoxicity of Parthenolide on normal cells that lead to reduction of drug side effects, it could be suggested as an adjuvant therapy with Epirubicin after complementary research on animal model and clinical trial.